middle.news
Bioxyne Boosts FY25 Revenue Guidance to $25M on Record Half-Year Growth
2:41pm on Thursday 23rd of January, 2025 AEDT
•
Life Sciences
Read Story
Bioxyne Boosts FY25 Revenue Guidance to $25M on Record Half-Year Growth
2:41pm on Thursday 23rd of January, 2025 AEDT
Key Points
FY2025 revenue guidance upgraded to $25 million
H1 FY2025 revenue surged 267% to approximately $12.6 million
Four consecutive quarters of positive cash flow expected in FY25
Breathe Life Sciences granted GMP license for medical cannabis and novel psychotropic manufacturing
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bioxyne (ASX:BXN)
OPEN ARTICLE